GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aurobindo Pharma Ltd

Aurobindo Pharma Q2 FY27 Net Profit Rises 32.5% YoY to INR 1,124 Cr

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Nov 2026, 08:03 PM IST  ·  BSE ID: faeb990a-1c1e-4438-ab88-6c25092cadf6
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma's latest quarterly profit and sales both significantly increased, with strong growth in key international markets.
🤖 AI Summary
  • Aurobindo Pharma reported Q2 FY27 Net Profit of INR 1,124 Cr, increasing 32.5% YoY.
  • Revenue from Operations for Q2 FY27 reached INR 10,263 Cr, a 23.9% increase YoY.
  • US revenue grew 25% YoY to INR 4,555 Cr, and Europe revenue rose 27% YoY to INR 3,161 Cr.
  • EBITDA for the quarter increased 28.5% YoY to INR 2,156 Cr, with a margin of 21.0%.
  • The company declared an interim dividend of ₹ 7.0 per share for shareholders.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
10,263 INR Cr
23.9%
EBITDA (Q2 FY27)
2,156 INR Cr
28.5%
Net Profit for the period (Q2 FY27)
1,124 INR Cr
32.5%
EBITDA Margin (%) (Q2 FY27)
21.0%
75 bps
US revenue (Q2 FY27)
4,555 INR Cr
25%
Europe revenue (Q2 FY27)
3,161 INR Cr
27%
Interim dividend per share
7.0 ₹
🏢 How This Affects the Company
📈
Business Impact
The company recorded its highest ever quarterly Revenue from Operations at INR 10,263 Cr, indicating sustained growth across its diversified businesses. Strong performance in US and Europe, along with 12 new USFDA final approvals, expands its product portfolio and market presence.
💰
Financial Impact
Net Profit for Q2 FY27 increased by 32.5% YoY to INR 1,124 Cr, improving profitability. EBITDA margin expanded to 21.0%, up 75 bps YoY, reflecting operational efficiency. The company generated strong free cash flows of USD 146 million and maintained a net cash position of USD 189 million.
⚙️
Operational Impact
R&D expenditure increased to INR 376 Cr in Q2 FY27 from INR 344 Cr in Q1 FY27, supporting new product development and future launches. The cumulative filing of 900 ANDAs with USFDA and 747 final approvals demonstrates ongoing regulatory activity and product pipeline strength.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are not required to take immediate action based on this financial results announcement, other than noting the interim dividend declaration.
👤
Who Is Affected
All shareholders are affected by the company's financial performance. Those holding shares before the record date will be eligible for the interim dividend of ₹ 7.0 per share.
🔍
Management Signal
The declaration of an interim dividend and positive commentary from management signal confidence in the company's current performance and future outlook, with focus on sustainable growth and financial discipline.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — check for continued revenue and profit growth.
Updates on USFDA approvals and new product launches in key markets.
Announcement of the record date for the declared interim dividend.
LOW RISK The filing indicates strong financial performance and operational stability with positive growth across key segments.
💡 Investor Takeaway
Aurobindo Pharma reported Q2 FY27 consolidated Revenue from Operations at INR 10,263 Cr, up 23.9% YoY, achieving its highest ever quarterly revenue. Net Profit for the period increased 32.5% YoY to INR 1,124 Cr, while EBITDA margin improved to 21.0%. An interim dividend of ₹ 7.0 per share was declared.
⚖️ Strengths & Concerns

✅ Positives

  • Revenue from Operations reached a record high of INR 10,263 Cr in Q2 FY27, marking a 23.9% increase YoY.
  • Net Profit for the period grew 32.5% YoY to INR 1,124 Cr, alongside a 75 bps YoY expansion in EBITDA Margin to 21.0%.

⚠️ Concerns

  • Growth Markets revenue decreased by 3.5% QoQ to INR 1,026 Cr, indicating a quarterly dip in this segment.
  • ARV revenue remained broadly stable at INR 359 Cr, accounting for only 3% of consolidated revenue, showing limited growth contribution.
📅 Company Track Record
In Q1 FY27, Aurobindo Pharma reported a Net Profit of INR 1,032 Cr, representing a 25.2% YoY increase. Prior to that, Q1 FY26 Profit After Tax was INR 7,372.2 million, up 31.85% YoY.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Aurobindo Pharma's Net Profit for Q2 FY27?
Aurobindo Pharma's Net Profit for Q2 FY27 was INR 1,124 Cr, which is a 32.5% increase compared to INR 848 Cr in Q2 FY26.
What was Aurobindo Pharma's Revenue from Operations in Q2 FY27?
The Revenue from Operations for Aurobindo Pharma in Q2 FY27 was INR 10,263 Cr, marking a 23.9% increase from INR 8,286 Cr in Q2 FY26.
What was the growth in Aurobindo Pharma's US and Europe revenues in Q2 FY27?
US revenue increased by 25% YoY to INR 4,555 Cr, and Europe revenue grew by 27% YoY to INR 3,161 Cr in Q2 FY27.
What interim dividend did Aurobindo Pharma declare for Q2 FY27?
Aurobindo Pharma declared an interim dividend of ₹ 7.0 per share for Q2 FY27.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.